ReviewTargeted oncology2023

Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.

Jiayu Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.